The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

Australian cancer ... help. Patient groups and experts are calling on Health Minister Mark Butler to intervene and overrule ...

There remains uncertainty about how much longer Keytruda can help patients live ... extra life was likely to be more than 3 months. Lung cancer kills more people than any other form of cancer ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment ... portfolio with the goal to help even more patients affected by this type of cancer.” ...

Participants will be randomly assigned to receive either V940 and KEYTRUDA or a placebo and KEYTRUDA, with the primary endpoint being disease-free survival. Lung cancer remains the ... The information ...

“While the overall survival rates for patients with non-small cell lung cancer have significantly ... of a patient’s tumor. KEYTRUDA is an immunotherapy that works by increasing the ability of the ...

Merck's Keytruda has been ... is a small biotech company that does not currently generate any revenue. The company's leading candidate, ivonescimab, is a lung cancer drug. Back in September ...

Does that mean investors ... ivonescimab in treating non-small cell lung cancer (NSCLC) patients with a PD-L1 protein ...